Larimar Therapeutics DEF 14A: Executive Compensation Details
Ticker: LRMR · Form: DEF 14A · Filed: Apr 11, 2025 · CIK: 1374690
| Field | Detail |
|---|---|
| Company | Larimar Therapeutics, Inc. (LRMR) |
| Form Type | DEF 14A |
| Filed Date | Apr 11, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
Related Tickers: LRMR
TL;DR
LRMR DEF 14A out: exec comp & equity awards for 2024 detailed.
AI Summary
Larimar Therapeutics, Inc. (LRMR) filed a DEF 14A on April 11, 2025, detailing executive compensation and related matters for the fiscal year ending December 31, 2024. The filing includes information on changes in the fair value of outstanding equity awards granted in prior years to both principal executive officers (PEO) and non-PEO members, as well as equity awards that vested during the covered year.
Why It Matters
This filing provides transparency into how Larimar Therapeutics compensates its top executives, which can influence investor perception and executive decision-making.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of executive compensation and does not present new material risks.
Key Numbers
- 2024 — Fiscal Year End (Compensation data pertains to this fiscal year.)
- 20250411 — Filing Date (Date the DEF 14A was filed with the SEC.)
Key Players & Entities
- Larimar Therapeutics, Inc. (company) — Filer
- ZAFGEN, INC. (company) — Former company name
- 0000950170-25-053028 (filing_id) — Accession Number
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is filed by companies to solicit proxies from shareholders for an upcoming annual or special meeting. It provides detailed information on matters to be voted on, including executive compensation, director elections, and other corporate governance issues.
What specific compensation-related data is detailed in this filing for Larimar Therapeutics?
This filing details changes in the fair value of outstanding equity awards granted in prior years to both principal executive officers (PEO) and non-PEO members, as well as equity awards that vested during the covered year (2024).
What was Larimar Therapeutics' former company name?
Larimar Therapeutics, Inc. was formerly known as ZAFGEN, INC. and ZAFGEN INC.
When was the company name changed from ZAFGEN, INC.?
The company name was changed from ZAFGEN, INC. on March 1, 2010.
What is the standard industrial classification for Larimar Therapeutics?
Larimar Therapeutics, Inc. falls under the Standard Industrial Classification code 2834, which is for Pharmaceutical Preparations.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 11, 2025 regarding Larimar Therapeutics, Inc. (LRMR).